Tokyo-1 aims to transcend corporate boundaries, empowering each research member to pursue innovation without being confined by traditional concepts or constraints. We are actively seeking dedicated individuals to join us in reshaping Japan’s pharmaceutical industry and pioneering the future. We are confident that participating in Tokyo-1 is a significant step towards revolutionary drug discovery, making a substantial impact on the future of healthcare.
Pharmaceutical Company
Astellas Pharma is pursuing innovative digital solutions across its business --- including in sales, manufacturing, and research and development --- to maximize outcomes for patients and reduce the costs of healthcare. With Tokyo-1, the company will accelerate its research with molecular simulations and large language models for generative AI. We will explore a wide range of applications including small molecule compounds, antibodies, gene therapy, cell therapy, targeted protein degradation, engineered phage therapy and mRNA medicine. By enabling us to take full advantage of recent advances in AI and simulation technology, we expect that Tokyo-1 will be one of the foundations on which Astellas can achieve its VISION for the future of pharmaceutical research.
Pharmaceutical Company
Ono Pharma, based on its corporate philosophy of "Dedicated to the Fight against Disease and Pain.", aims to become a company with high dynamic capabilities by utilizing digital and IT, even as the business environment undergoes significant changes. To achieve this, it is necessary to have an internal and external data utilization environment, data analysis capabilities from a unique perspective, and a flexible IT infrastructure supported by the latk1 technologies.
By establishing an IT infrastructure, we can use internal and external data to timely and accurately detect and judge business challenges and new opportunities and reflect and implement them in our business transformation plans.
The construction of AI models often requires immense computational power, and we believe that the substantial GPU power of Tokyo – 1 can address such challenges. This supercomputer, based on DGX, is thought to have a very wide range of applications, including high-quality simulations, image analysis, video analysis, and language models.
Pharmaceutical Company
Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in 29 countries/regions around the world. With more than 120 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients. Through the outstanding knowledge and commitment of our 17,000 + employees worldwide, we create innovative new and generic medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.